Compare ALGS & NPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALGS | NPT |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Chemicals |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.0M | 29.7M |
| IPO Year | 2020 | N/A |
| Metric | ALGS | NPT |
|---|---|---|
| Price | $5.51 | $2.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $39.33 | N/A |
| AVG Volume (30 Days) | 83.9K | ★ 7.1M |
| Earning Date | 05-05-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,186,000.00 | N/A |
| Revenue This Year | $32.20 | N/A |
| Revenue Next Year | $4.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.80 | $1.14 |
| 52 Week High | $13.69 | $22.38 |
| Indicator | ALGS | NPT |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 50.00 |
| Support Level | $4.80 | $1.19 |
| Resistance Level | $6.82 | $3.21 |
| Average True Range (ATR) | 0.36 | 1.21 |
| MACD | 0.09 | 0.05 |
| Stochastic Oscillator | 55.34 | 9.15 |
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Texxon Holding Ltd provides technology-enabled supply chain management services to customers in the plastics and chemical industries in East China. The company operates through two segments: Supply Chain Trading and Plastic Manufacturing. Its services include procurement, logistics, payments, and fulfillment for Chinese SMEs, and all revenue is generated from operations within the People's Republic of China.